In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on UnitedHealth (NYSE: UNH), with a price target of $361.00. The company’s shares closed last Wednesday at $294.60.
UnitedHealth has an analyst consensus of Strong Buy, with a price target consensus of $348.25.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return 17.2% and a 69.8% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Community Health, The Ensign Group, and Addus Homecare.
UnitedHealth’s market cap is currently $292.7B and has a P/E ratio of 16.80. The company has a Price to Book ratio of -19.21.
Based on the recent corporate insider activity of 142 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UNH in relation to earlier this year.
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum’s capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health services business serving the broad health care marketplace, including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the health care industry. The OptumRx segment provides pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minneapolis, MN.